Author | Dianne Tomita, MPH

Articles

Every-2-Week Darbepoetin Alfa Is Comparable to rHuEPO in Treating Chemotherapy-Induced Anemia

October 01, 2002

ByBarry Mirtsching, MD

Veena Charu, MD

Saroj Vadhan-raj, MD

Alan B. Colowick, MD, MPH

Gregory Rossi, PhD

Dianne Tomita, MPH

William P. Mcguire Iii, MD

The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 µg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by